CLENE INC. news, videos and press releases
For more news please use our advanced search feature.
CLENE INC. - More news...
CLENE INC. - More news...
- FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS
- Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights
- Clene to Present at Upcoming October Conferences
- Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility
- Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules
- Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data
- Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights
- Clene Announces New CNM-Au8® Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS
- Clene to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
- Clene to Present at the Emerging Growth Conference
- Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS
- Clene Announces 1-for-20 Reverse Stock Split
- Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference
- Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome
- Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting
- Clene to Present at the Emerging Growth Conference
- Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)
- Clene to Present at Upcoming May Conferences
- Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights
- Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
- Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®
- Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
- Clene to Present at the 36th Annual ROTH Conference
- Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024
- Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs
- Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension
- Clene Provides Update on ALS Clinical Development Meeting With FDA
- Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension
- Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases
